Table 1.
SLE# | Gender | Age | SLEDAI | Duration (year) | dsDNA (U/mL) | C3 (mg/dL) | C4 (mg/dL) | WBC (/mm3) | PLT (1,000/mm3) | HgB (g/dL) | Arthritis | Nephritis | Hepatitis§ | Cohort | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 40 | 6 | 13 | 53.5 | 64.8 | 19.5 | 9250 | 402 | 12.1 | 1 | 1 | 1 | 1 | |
2 | F | 21 | 4 | 1 | 62.4 | 61.6 | 14.2 | 4210 | 317 | 12.8 | 1 | 0 | 0 | 1 | |
3 | F | 27 | 6 | 3 | 11.8 | 71.1 | 19.2 | 8600 | 252 | 12.9 | 1 | 0 | 0 | 1 | |
4 | F | 20 | 12 | 2.5 | 49.6 | 99.5 | 15.0 | 3670 | 205 | 12.2 | 1 | 1 | 0 | 1 | |
5 | F | 66 | 10 | 0.2 | 114.0 | 56.8 | 6.6 | 3400 | 203 | 10 | 1 | 0 | 1 | 2 | |
6 | F | 42 | 2 | 0.3 | 0.0 | 128.0 | 33.7 | 12,000 | 262 | 14.1 | 1 | 0 | 1 | 2 |
Cohort #1, patients from the Division of Immunology and Rheumatology at Taichung Veterans General Hospital in Taiwan.
Cohort #2, patients from the Division of Immunology and Rheumatology at Taipei Veterans General Hospital in Taiwan.
§, patients with hepatitis during 2018-2020.
F, female; SLEDAI, SLE disease activity index; C3, complement component C3; C4, complement component C4; WBC, white blood cell; PLT, platelet; HgB, haemoglobin.